Camurus ABCAMRF -3.57%79 Quick Ratio is 11.28 as of Mar. 2026, which is 209% above its 10-year median of 3.65. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Camurus AB ranks better than 81.44% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Camurus AB's quick ratio for the quarter that ended in Mar. 2026 was 11.28.
Camurus AB has a quick ratio of 11.28. It generally indicates good short-term financial strength.
The historical rank and industry rank for Camurus AB's Quick Ratio or its related term are showing as below:
CAMRF'
s Quick Ratio Range Over the Past 10 Years
Min: 1.4 Med: 3.65 Max: 11.78
Current: 11.28
During the past 13 years, Camurus AB's highest Quick Ratio was 11.78. The lowest was 1.40. And the median was 3.65.
CAMRF's Quick Ratio is ranked better than 81.44% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs CAMRF: 11.28
Camurus AB (OTCPK:CAMRF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Camurus AB Quick Ratio Related Terms
Camurus AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Camurus AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Quick Ratio of 11.28 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Camurus AB and its competitors. This is 209% above median its historical median of 3.65. Over the past decade, Camurus AB's Quick Ratio has ranged from 1.40 to 11.78. According to the industry distribution chart, Camurus AB ranks #263 out of 1417 companies in the Biotechnology industry, placing it in the top 18.6%.
Is Camurus AB's Quick Ratio too high?
Camurus AB's current Quick Ratio of 11.28 is 209% above median its 10-year median of 3.65. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 11.78. The Biotechnology industry median Quick Ratio is 3.60. Camurus AB's value of 11.28 is 213.3% above this industry median. Based on the distribution chart, Camurus AB ranks #263 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #263 out of 1417 companies for Quick Ratio. This places Camurus AB in the top 19% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Camurus AB's value of 11.28 is 213.3% above this benchmark. Historically, Camurus AB's own Quick Ratio has ranged from 1.40 to 11.78 over the past decade. While the company's 10-year median is 3.65 vs. the industry median of 3.60, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Quick Ratio of 11.28 is 213.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Quick Ratio is 11.28, which is 209% above median its own 10-year median of 3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Quick Ratio is 11.28, which is 209% above median its 10-year median of 3.65 and 213.3% above the Biotechnology industry median of 3.60. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Quick Ratio is 11.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
Quick Ratio: 11.28 (209% above median its 10-year median of 3.65)
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
Industry Position: 213.3% above the Biotechnology median (#263 of 1417)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
